has been engaged by hundreds of organizations seeking
clinical trial management, proprietary technology solutions, business
advisory services and funding—all in service of the development of
innovative therapies and treatments.
Over the past twelve years, we have managed successful engagements for organizations including:
is seeking opportunities to provide game changing
services in the life science sector. As a trusted partner to many
leading pharmaceutical companies, Numoda offers expertise in:
If you are seeking a strong partner to take your company to the next level please contact us at
Commitment to a new model of efficiency, cost
effectiveness, and success for the development of revolutionary
therapies and treatments for the benefit of patients worldwide
Passion for giving organizations superior service and solutions to complete their intended missions
.
Drive to improve every aspect of the life
sciences enterprise—from funding, to testing, to partnering for access
to commercialization partners and markets.
Numoda Corporation is a fifteen-year-old company headquartered in Philadelphia, with operations in 50 countries.
Three organizations work in harmony and collaborate for improved clinical outcomes and investment results:
Numoda Corporation – integrates every aspect of
clinical trial development under The Accountable General Contractor,
with unparalleled accountability of all suppliers, groups and
participants for the life sciences.
Numoda Technologies, Inc – builds and maintains
the patented platforms of integrations, logistics management, and
financial oversight for clinical development and efficient trial and
data management.
Numoda Capital Innovations – enables life
sciences companies to attract capital and partners while investing
directly in companies with promising new therapies and treatments.
News At Glance :
Zack's Investment Research(click here)
February 2012
Advaxis Reports Positive Phase II Trial Results
"...The study is designed to assess the safety and efficacy of
ADXS-HPV for the treatment of CIN grade 2/3, which is late stage
cervical dysplasia that requires surgery to prevent invasive cancer.
Numoda Corporation is Advaxis’ strategic partner in the conduction and
execution of this trial.
"
One Med Place(click here)
January 2012
Advaxis CEO Tom Moore Interviewed by OneMedPlace Regarding Preliminary Data
"Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next
generation of immunotherapies for cancer and infectious diseases,
reports that Thomas Moore, CEO & Chairman of Advaxis, was
interviewed by Malini Chatterjee, Ph.D., Director of Research at
OneMedPlace, to discuss the preliminary safety and survival data from
the ongoing ADXS-HPV Phase 2 Trial in patients with recurrent/refractory
cervical cancer in India that were presented at the World Cancer
Immunotherapy Conference in San Diego on January 25, 2012..
"
The Street (click here)
January 2012
Pinnacle Biologics, Inc. Announces The Successful Completion Of A Financing Round
" Led by NUMODA CAPITAL INNOVATIONS, LLC., PINNACLE BIOLOGICS
announced today the succesful completion of a financing round, in a
combination of Equity, and Debt Conversion.
"
Med City News (click here)
December 2011
Numoda life science investment arm collaborates with stem cell technology company
- By Stephanie Baum
"Philadelphia technology company Numoda‘s life science investment arm,
Numoda Capital Innovations, has collaborated with IntelliCell
Bioscience, a New York-based company seeking to harvest adult adipose
stem cells derived from fat in a cost-effective manner.
"
Dow Jones Venture Wire (click here)
June 2011
With Drugs In Doubt, Some Biotechs Are Selling Out
- By Brian Gormely
"...Numoda now plans to develop Vitreosolve in the primary
indication of vitreomacular adhesion and the secondary indication of
inducing a posterior-vitreous detachment in the treatment of diabetic
retinopathy. The firm plans new, placebo-controlled studies and is
consulting drug-makers to find other ways to groom Vitreosolve for a
sale. It aims to speed the auctioning process through technology from
an affiliate, Numoda Technologies Inc., that enables potential bidders
to see trial data as they are generated."
Dow Jones Venture Wire (click here)
March 2011
Numoda Capital Buys VitreoRetinal Assets, Seeks To Revive Vision Drug
- By Brian Gormely
"Numoda Capital Innovations is reviving an effort to develop a
drug for the blinding disease diabetic retinopathy that stalled in the
hands of venture-backed VitreoRetinal Technologies Inc."
January 2011
After announcing positive top-line results from a large, global
Phase III clinical trial that Numoda managed and partially funded
through an investment, stakeholders experienced a 46% gain in share
price. Since the study began, $83MM in market value was created for
our client, as well as a significant licensing deal.
If you would like to learn more about how these results can
benefit you please visit us at the JP Morgan 2011 Healthcare Conference.
Contact
Christopher Mather, SVP Business Affairs, for appointments.
Crain's Detroit Business (click here)
October 2010
MichBio Expo attendees hear ways to get VC funding for startups
- By Shawn White
..."There has been a decrease in number of biotech and medical
investments overall," said Mary Schaheen, CEO of Philadelphia-based
Numoda Corp.
"But there have been a lot of very creative sources for funds:
grants, alliances, high net worth investors and consolidation."...
Pharmawire(click here)
October 2010
Marina retains Numoda for Phase Ib/IIa trial of lead compound;
open to contact from other CROs for pivotal Phase IIb - CEO
-by Anusha Kambhampaty
...The company will work with Numoda for the 30 patient trial that will assess the knock-down of betacatenin
in the epithelial cells of the small and large intestine regions where beta-catenin is
known to be dysregulated in FAP...
World Market Media(click here)
July 2010
Provectus Scores Points with Numoda Capital
- By Steven Michael King
... Numoda’s TruPoints platform already has an excellent
reputation for helping numerous development stage biotech companies
secure big pharma licensing agreements...
MedCityNews (click here)
July 2010
Cleveland Clinic, Numoda partner to speed brain drugs to market
- By Mary Vanac
...The goal is to speed effective neurological drugs to market
and quickly weed out those that don’t work, while lowering the cost of
drug development. ....
July 2010
Dow Jones Venture Wire (click here)
June 2010
Numoda Forms Cleveland Clinic Alliance; Deal Will Feed Venture Arm
- By Brian Gormely
...Numoda said its technology and services can also help
companies catch and fix problems that are occurring in clinical studies.
Numoda will also provide researchers at Cleveland Clinic's
Neurological Institute with information systems, reporting engines and
administrative tools to help improve patient recruitment, budgeting
and data flow. ....
Venture Capital Dispatch - WSJ (click here)
January 2010
JPMorgan Conference Lifts Biotech VC Hopes For Pharma Deals
- By Brian Gormely
...Pharmaceutical companies at the conference were looking to
spin products out as well as bring them in, said Terrance McGovern,
managing director, Numoda Capital Innovations, an investment affiliate
of Numoda Corp. ....
Dow Jones Venture Wire (click here)
August 2009
MediQuest Therapeutics Takes Streamlined Route To VC Liquidity
- By Brian Gormely
...Numoda Capital also works with these companies to help them
find strategic partners. The group aims to connect MediQuest with
pharmaceutical companies interested in licensing Vascana and other
pipeline drugs....
The Wall Street Journal (click here)
April 2009
Clinical Trials Manager Heads Into VC
- By Scott Austin
...Numoda’s track record of helping companies reduce the cost and risk of drug development should appeal to investors...
Dow Jones Venture Wire (click here)
April 2009
Numoda Seeks $150M Debut Health Fund
- By Brian Gormely
...“From a financial perspective, we can de-risk the process,” Schaheen said. “Our job is to get time, quality and
money in balance.”...
C.E. Unterberg Business Analyst (click here)
June 2007
...Enrollment nearing completion....
Harvard Business Review (click here)
October 2006
...Managing risk and rewarding risk taking, integrating the
skills and capabilities that reside in a range of disciplines...
Charite Artificial Spinal Replacement Disc approved
by U.S. regulators within a year. (click here)
...for a recently concluded medical device study, sponsored by
DePuy Spine (formerly Link Spine Group). This new prosthesis is an
artificial spinal disc that provides a wider range of motion for the
patient. The procedure is expected to replace spinal fusion surgery.
